Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD

NCT02298283 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: brentuximab vedotin
DRUG: Cyclophosphamide
DRUG: Adriamycin
DRUG: Oncovin
DRUG: Bleomycin
DRUG: Etoposide
DRUG: Procarbazine
DRUG: Prednisone
DRUG: G-CSF
RADIATION: 30 Grays

Sponsor

The Lymphoma Academic Research Organisation